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OBJECTIVE
To determine trends in hospitalization for hypoglycemia in adults with type 1 di-
abetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in England.
RESEARCH DESIGN AND METHODS
Adults with T1DM or T2DMwere identified from 398 of the 684 practices within the
Clinical Practice Research Datalink, for which linkage to the Hospital Episode Stat-
istics was possible. Hypoglycemia as the primary reason for hospitalization between
1998 and 2013 was extracted. Trends were estimated using joinpoint regression
models for adults with T1DM, young and middle-aged adults with T2DM (18–64
years), and elderly adults with T2DM (‡65 years), respectively.
RESULTS
Among 23,246 adults with T1DM, 1,591 hypoglycemia hospitalizations occurred dur-
ing 121,262 person-years. Among 241,441 adults with T2DM, 3,738 hypoglycemia
hospitalizations occurred during 1,344,818 person-years. In adults with T1DM, the
incidence increased 3.74% (95% CI 1.70–5.83) annually from 1998 to 2013. In young
and middle-aged adults with T2DM, the annual incidence increase was 4.12% (0.61–
7.75) from 1998 to 2013. In elderly adults with T2DM, the incidence increased 8.59%
(5.76–11.50) annually from 1998 to 2009, and decreased 8.05% (214.48 to 21.13)
annually from 2009 to 2013, but the incidence was still higher in 2013 than 1998 (ad-
justed rate ratio 3.01 [1.76–5.14]). Trends in HbA1c level did not parallel trends of
hypoglycemia hospitalization for both diabetes types. A possible reason for declined
hypoglycemia trend in 2009–2013 in elderly adults with T2DM may be continuously
decreased sulfonylurea use after 2009,whichwasnot seen in youngandmiddle-aged
adults with T2DM.
CONCLUSIONS
Hypoglycemia requiring hospitalization has been an increasing burden in adults with
T1DM and T2DM in England in the previous two decades, with the exception of the
decline in elderly adults with T2DM starting in 2009.
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Hypoglycemia is a common but prevent-
able complication in diabetes (1). In the
past few decades, tremendous progress in
diabetes management has been made,
including the shift in diabetes guide-
lines from emphasizing hyperglycemia
control toward recommending individual-
izedglycemic targets tobalancehyper- and
hypoglycemia risk (2,3), introduction of
newdrugs (e.g., dipeptidyl peptidase-4 in-
hibitors, glucagon-like peptide 1 receptor
agonists, and sodium-glucose cotransporter-
2 inhibitors) that are associated with low
hypoglycemia risk (4,5), and availability of
new technologies such as continuous glu-
cose monitoring and insulin pump (6,7).
However, it is not clear whether these
trends in diabetes management have led
to a decline in hypoglycemia risk in adults
with diabetes. Particularly, it is not clear if
trends of hypoglycemia differ by diabetes
type.
The etiology and treatment of type 1
diabetes mellitus (T1DM) and type 2 di-
abetes mellitus (T2DM) are different,
leading to very different hypoglycemia
risk (1). Long-term trend studies on hypo-
glycemia that do not distinguish diabetes
type are not able to provide clear data for
informing targeted practice-level and
policy-level intervention. Previous stud-
ies focused on describing hypoglycemia
trends in a health care system or in peo-
ple with diabetes without regard to type
(8–13). To our knowledge, for adults with
T1DM, only one Danish study reported
decreased trends for hospitalization for
hypoglycemia from 2006 to 2012 (14).
Only two studies reported trends of se-
vere hypoglycemia specifically in adults
with T2DM, but with different findings.
Lipska et al. (15) found stable rates of se-
vere hypoglycemia between 2006 and
2013 in the U.S. Chen et al. (16) reported
a 10-year increase (2000–2010) in the in-
cidence of hypoglycemia-related emer-
gency department visits in Taiwan.
In the current study,we aimed to study
hypoglycemia that requires hospital ad-
mission, which is a most severe form of
hypoglycemia and associated with con-
siderablemorbidity, mortality, and health
care resource use and expenditure (17).
In England, trends of hypoglycemia
hospitalization were recently reported
by Zaccardi et al. (12) in the entire
health care system, but diabetes type–
specific trends were unknown. The main
goal of our study was to characterize
incidence and trends of hypoglycemia
hospitalization among adults with T1DM
or T2DM between 1998 and 2013, both
overall and according to key patient char-
acteristics. Data were from the Clinical
Practice Research Datalink (CPRD) and
Hospital Episode Statistics (HES) from
theU.K.We hypothesized that the annual
incidence increased first because of em-
phasizing hyperglycemia control since the
Diabetes Control and Complications Trial
(DCCT) (18) and then decreased due to 1)
recent recommendations of individual-
ized glycemic management for hypogly-
cemia risk reduction and 2) negative
findings on the cardiovascular benefits
of more aggressive glycemic control ther-
apy from the three randomized trials
published in 2008 and 2009, the Action
to Control Cardiovascular Risk in Diabetes
(ACCORD) trial (19), the Action in Diabe-
tes and Vascular Disease (ADVANCE) trial
(20), and the Veterans Affairs Diabetes
Trial (VADT) (21). Trends in hypoglycemia
hospitalization may vary by diabetes type
and patient characteristics.
RESEARCH DESIGN AND METHODS
Data Sources
Established in 1987, the CPRD included
684 practices from England, Scotland,
Wales, and Northern Ireland and con-
tained over 15 million patient records
as of January 2015. Patients in the
CPRD are broadly representative of
age, sex, and ethnicity of the U.K. pop-
ulation (22). Clinical entries in the CPRD
are coded using Read codes, a hierarchi-
cal clinical coding system used in general
practice in the U.K. (23). The HES is a data
warehouse storing records of all patients
admitted to National Health Service hos-
pitals in England only. Patient-level data
from consenting CPRD practices are
linked to the HES data via a trusted third
party (22). The HES data used for the cur-
rent study included admitted patient care
informationfrom1April 1997 to31March
2014. ICD-10 codes are used within the
HES. Hypoglycemia hospitalizations were
identified from theHES. All other informa-
tion, including diabetes diagnosis, demo-
graphics, and prescriptions, was extracted
from the CPRD. The study protocol
(15_259RA) was approved by the Inde-
pendent Scientific Advisory Committee
for Medicines and Healthcare Products
Regulatory Agency in the U.K. and the in-
stitutional review boards at the University
of North Carolina at Chapel Hill in the U.S.
Definition of T1DM and T2DM
As of 31March 2014, 398 of the 684 CPRD
practices were linked to the HES and thus
were included in our study, accounting
for;60% of the entire CPRD population.
The linked CPRD-HES population is repre-
sentative of the entire CPRD population
(24). Patients with one or more diabetes-
related Read code were first identified
(25). Patients were then excluded if they
had any record of secondary diabetes,
maturity-onset diabetes of young, la-
tent autoimmune diabetes in adults, or
malnutrition-related diabetes or did not
meet the research standards established
by the CPRD team. Patients were labeled
as “unacceptable” by the CPRD teamwho
were identified by a systematic process
with noncontinuous follow-up or poor
data recording based on a number of
prespecified data quality metrics.
Criteria to identify diabetes type were
adopted from relevant CPRD literature,
with modifications to reflect specific dif-
ferentiation between T1DM and T2DM
(26–28). Among those with at least one
diabetes-related code, T1DM was iden-
tified if one of the following criteria was
met: 1) one or more T1DM code and use
of insulin only; 2) one ormore T1DMcode
and use of insulin only on the diagnosis
date and noninsulin glucose-lowering
drug (NIGLD), if any, was introduced
6 months later; or 3) two or more insulin
prescriptions only and one or more un-
specified diabetes code. T2DM was de-
fined as any of the following: 1) two or
more T2DM codes and zero T1DM codes,
regardless of drug use; 2) one or more
T2DM codes and zero T1DM codes and
NIGLD only; 3) one or more T2DM codes
and zero T1DM codes and on NIGLD and
insulin, but NIGLD prescribed no later
than insulin; 4) two or more classes of
NIGLD; or 5) two or more prescriptions
of a noninsulin, nonmetformin glucose-
lowering drug only and one or more un-
specified diabetes code. NIGLDs included
metformin, sulfonylureas, glinides, thia-
zolidinediones, dipeptidyl peptidase-4 in-
hibitors, sodium-glucose cotransporter-2
inhibitors, glucagon-like peptide 1 recep-
tor agonists, and acarbose.
Study Period and Definition of
Hypoglycemia Hospitalization
The study period was between 1 January
1998 and 31 December 2013 when full-
year HES data were available. The follow-
up started at the maximum date of the
following: 1 January 1998, first diabetes
visit, patient registration, up to standard
(UTS) date, or 18 years old. UTS is the date
at which the practice data are deemed to
be of research quality (22). Follow-up
ended at theminimumdate of the follow-
ing: 31 December 2013, death, transfer
out, or last data collection for the prac-
tice. Hypoglycemia (E16.0, E16.1, and
E16.2) listed as the primary diagnosis for
hospitalization during the follow-up pe-
riod was identified. We included all epi-
sodes of hypoglycemia hospitalization.
Statistical Analysis
All analyses were performed separately
for T1DM and T2DM. Treatment guide-
lines for T2DM vary according to an indi-
vidual’s hypoglycemia risk factors, such as
age, current use of glucose-lowering
drugs, number of comorbidities, duration
of diabetes, history of severe hypoglyce-
mia, and life expectancy (2,3). Therefore,
separate analyses were performed in
young and middle-aged adults with
T2DM (18–64 years) and elderly adults
with T2DM ($65 years).
Incidence rates of hypoglycemia hos-
pitalization were calculated by dividing
the total number of hypoglycemia hospi-
talization by total accumulated person-
years with diabetes within each year
between 1998 and 2013. The accumu-
lated person-years for a patient were ob-
tained by subtracting the follow-up start
date from the follow-up end date, which
was then divided by 365.25. Stratified in-
cidence rates were also computed. For
adults with T1DM, incidence rates were
calculated by age (18–44, 45–64, 65–79,
and $80 years), sex, and length of re-
corded diabetes history (as an alternative
for diabetes duration: 0–4, 5–9, 10–14,
and $15 years). For young and middle-
aged adults with T2DM, incidence rates
were calculated by age (18–44 and 45–
64 years), sex, lengthof recordeddiabetes
history (0–9 and $10 years), and current
use of glucose-lowering drugs (insulin
with/without NIGLD, sulfonylureas with/
without other NIGLD, and “other”). For
elderly adults with T2DM, incidence rates
were calculated by age (65–79 and $80
years), sex, length of recorded diabetes
history (0–4, 5–9, 10–14, and$15 years),
and current use of glucose-loweringdrugs
(insulin only, insulin and NIGLD, sulfonyl-
ureas only, sulfonylureas and other
NIGLD, and “other”). All rates were re-
ported per 1,000 person-years.
We applied joinpoint regression mod-
els to quantify trends for both overall and
stratified incidence rates (29). Each join-
point (i.e., specific year) denoted a statis-
tically significant change in trend. We
fitted a heteroscedastic and uncorrelated
error joinpoint regression model and
allowed a maximum of three joinpoints.
A grid search was used to identify loca-
tions of joinpoint(s). We selected the
best-fitting model by conducting a series
of permutation tests based on 4,500
Monte Carlo replicates, using aBonferroni
correction for multiple testing (30). Pa-
rameters in the model were estimated
using weighted least squares, with
weights proportional to the inverse of
the variance of the incidence rate at
each year. Annual percentage change
and 95% CI were estimated.
Two sensitivity analyses were con-
ducted to evaluate whether the potential
misclassification of diabetes typemay im-
pact obtained hypoglycemia trends. First,
the proportion of patients identified by
each criterion of our case definition was
calculated. We reran joinpoint regression
models to determine trends after remov-
ing patients identified by the criteria that
from a clinical perspective were most
likely associated with misclassification.
Second, we considered definitions for
T1DM and T2DM used in three previous
CPRD studies (26–28). For T1DM, the
T1DM case definitions in the CPRD litera-
ture generally included young age, such
as,35 years, as a criterion. However, it is
well known that the T2DM prevalence
has been increasing in children and young
adults (31). Thus, hypoglycemia trends
were not examined using exactly the
same published definitions for T1DM be-
cause of the potential to incorrectly in-
clude individuals with T2DM. For T2DM,
we reran joinpoint analyses using the
same definitions as previously used in
the CPRD (26–28).
To compare the difference of the inci-
dence of hypoglycemia hospitalization by
year, we fitted a negative binomial reg-
ression model with the number of hos-
pitalizations as the outcome and the
logarithm of person-years as the offset.
Using year 1998 as the reference, we in-
cluded 15 dummy year variables, repre-
senting subsequent years from 1999 to
2013 and adjusted for age, sex, length of
recorded diabetes history, and current
use of glucose-lowering drugs. Incidence
rate ratio (IRR) and95%CIwere estimated.
We also described the changes over time
in glycemic control (i.e., HbA1c), glucose-
lowering drugs, age, length of recorded
diabetes history, BMI, and Charlson co-
morbidity score (32) to help understand
the changes of the study population’s
characteristics. SAS (version 9.4; SAS In-
stitute Inc.) and Joinpoint software were
used to perform analyses (29). Statistical
significance was indicated by a two-sided
P value,0.05.
RESULTS
Among 23,246 adults with T1DM (Fig.
1), 1,591 hypoglycemia hospitalizations
occurred during 121,262 follow-up years
(Supplementary Table 1). Among 241,441
adultswith T2DM, 553hypoglycemia hos-
pitalizations were documented during
560,686 person-years of follow-up among
young and middle-aged adults, and 3,185
hospitalizationswere documented during
784,132 person-years of follow-up among
elderly adults.
In adults with T1DM (Supplementary
Table 1), the incidence increased from
9.57 to 14.80 hospitalizations for hypogly-
cemia per 1,000 person-years between
1998 and 2013 (adjusted IRR 1.67 [95%
CI 1.14–2.43]). The incidence of hypogly-
cemia hospitalization increased 3.74%
([1.70–5.83], P = 0.001) annually (Table 1
and Fig. 2A). This increasing trend was
seen in all age subgroups (Supplementary
Fig. 1A) and inmales and females (Supple-
mentary Fig. 1B). However, the significant
increasing trend was found only in those
with the longest length of recorded dia-
betes history (Supplementary Fig. 1C).
In young and middle-aged adults with
T2DM, the incidence increased from 0.73
to 1.19 hospitalizations for hypoglyce-
mia per 1,000 person-years between
1998 and 2013 (adjusted IRR 1.52 [0.68–
3.38]). The annual percent increase was
4.12% (0.61–7.75, P = 0.02) (Table 1 and
Fig. 2B). This increasing trend was similar
between young (18–44 years) andmiddle-
agedadults (45–64years) (Supplementary
Fig. 2A), between males and females
(Supplementary Fig. 2C), and between
short and long length of recorded diabe-
tes history $10 years (Supplementary
Fig. 2E), respectively. The incidence in-
creased among current insulin users but
not current sulfonylureas users and
“other” users (Supplementary Fig. 2G).
In elderly adults with T2DM, the inci-
dence was 1.12 and 3.52 hospitalizations
for hypoglycemia per 1,000 person-years
in 1998 and 2013, respectively (adjusted
IRR 3.01 [1.76–5.14]). The incidence in-
creased 8.59% (5.76–11.50, P , 0.0001)
annually from 1998 to 2009 and de-
creased 8.05% (214.48 to 21.13, P =
0.03) annually from 2009 to 2013 (Table
1 and Fig. 2C). This nonlinear trend
was observed among two subgroups
of age (65–79 and $80 years) (Supple-
mentary Fig. 2B) and both sex groups
(Supplementary Fig. 2D). The trend dif-
fered by length of recorded diabetes
history (Supplementary Fig. 2F). The inci-
dence rate did not change among those
with the shortest length of recorded di-
abetes history (0–4 years). A nonlinear
trend was seen in the remaining three
groups with longer length of recorded di-
abetes history. The temporal trend dif-
fered by current use of glucose-lowering
drug(s) (Supplementary Fig. 2H). There
was a linear increasing trend in all groups,
except users of both insulin and NIGLD,
among whom a decline was observed
since 2009. Removing current insulin
and NIGLD users or two groups with
long length of recorded diabetes history
(10–14 and$15 years) from the analyses
did not alter the change in the trend hap-
pening in 2009 (Supplementary Table 2).
The mean HbA1c level did not change
much among adults with T1DM from
1998 to 2013 (Fig. 3A). The propor-
tion of individuals with HbA1c ,6.5%
(47.5 mmol/mol) decreased and the
other four higher HbA1c groups generally
remained stable. The mean HbA1c level
decreased among adults with T2DM
(Fig. 3B and C) before 2009 and then
started to rise. In young and middle-
aged adults with T2DM, the propor-
tion of individuals with HbA1c $8.5%
(69.4 mmol/mol) decreased whereas the
proportion of individuals with HbA1c 6.5–
7.4% (47.5–57.4 mmol/mol) increased;
the remaining two HbA1c groups re-
mained relatively unchanged. In elderly
adults with T2DM, a decreased propor-
tion in the three higher HbA1c groups
was seen whereas an increased propor-
tion was observed in the two lower HbA1c
groups.
For T2DM, the trends in the current
use of all classes of glucose-lowering
drugs were similar between young and
middle-aged adults (Supplementary Fig.
3A) and elderly adults (Supplementary
Fig. 3B), except that the current use of
sulfonylureas decreased during the entire
period in elderly adults, whereas in young
andmiddle-aged adults, the decreasewas
only seen before 2007. The average age
declined in adults with T1DM and slightly
declined in young andmiddle-aged adults
with T2DM but slightly increased in el-
derly adults with T2DM (Supplementary
Fig. 4A). For adults with T1DMand T2DM,
we observed increased length of re-
corded diabetes history (Supplementary
Fig. 4B), elevated BMI (Supplemen-
tary Fig. 4C), and higher Charlson comor-
bidity score over time (Supplementary
Fig. 4D).
The sensitivity analyses indicated the
robustness of our results. The criteria
that weremost likely tomisclassify diabe-
tes type only captured a small proportion
of patients with T1DM (11.86%) and
T2DM (0.33%) (Supplementary Tables
3 and 4). Removing them from analyses
did not change the results (Supplementary
Table 5). Of note, 14.72% of patients with
T1DMwhowere exclusively taking insulin
and had one or more T1DM code also
had a T2DM code (Supplementary Table
3). Further excluding these patients did
not change trends of hypoglycemia hos-
pitalization in T1DM (annual percent in-
crease 2.48% [0.10–4.91], P = 0.04). In
addition, the hypoglycemia trends esti-
mated using exactly the same published
T2DM case definitions were similar to the
trends obtained using our definition
(Supplementary Table 6).
CONCLUSIONS
In England, the incidenceof hypoglycemia
hospitalization increased from 1998
to 2013 among both adults with T1DM
and young and middle-aged adults with
T2DM. In elderly adults with T2DM,
after a sharp increase in years prior to
2009, a decline in the incidence of hypo-
glycemia hospitalization was observed
between 2009 and 2013. Nonetheless,
the incidence in 2013was still three times
that in 1998. Subgroup analyses did not
find a difference in hypoglycemia hospi-
talization trends by age and sex, but
heterogeneity was found by glucose-
lowering drugs. The HbA1c trends alone
could not explain hypoglycemia hospital-
ization trends. Continuously decreased
use of sulfonylureas may be a possible
reason for the declined hypoglycemia
hospitalization trend since 2009 among
elderly adults with T2DM.
A complicating factor for interpreting
HbA1c data is the introduction of the
Quality and Outcomes Framework (QOF)





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in 2004, under which general practi-
tioners have been financially incentivized
to meet clinical targets for patients with
diabetes. Kontopantelis et al. (33) found
that the QOF introduction did not impact
the already decreasing trend of the HbA1c
level during the study period 2000–2007.
Inappropriate glycemic control is a known
risk factor for hypoglycemia (34,35). How-
ever, our data showed that the HbA1c
trends did not parallel the trends in hypo-
glycemia hospitalization. As reported by
the DCCT study (34), change in HbA1c
level itself could only explain a small pro-
portion of the variation (,10%) for hypo-
glycemia risk. Also, the HbA1c level is
determined by a wide range of factors
(e.g., demographics, duration of diabetes,
glucose-lowering therapy and adherence,
diet, physical activity, and overall health
condition), andmost of these factors may
also influence hypoglycemia risk depen-
dent or independent of HbA1c (36). The
comparisonofHbA1c trendswith hypogly-
cemia trends at a population level is
further complicated by the U-shaped as-
sociation between HbA1c level and hypo-
glycemia risk found in T2DM (35).
According to our analyses, an increase
was seen in length of recorded diabetes
history, BMI, and Charlson comorbidity
score. However, this increase may be
the consequence of both population ag-
ing and more complete data recording
within the CPRD over time, particularly
after the QOF introduction (22,33). Thus,
we are not certain about the true effect of
population aging on observed trends in
hypoglycemia hospitalization in our study.
The mean age declined in adults with
T1DM and slightly decreased in young and
middle-aged adults with T2DM. This may
be driven by the rise of childhood T1DM
(37,38) and T2DM in children and young
adults (31).
The hypoglycemia trend identified in
adults with T1DM from our study is op-
posite that reported from the Danish
Register Linkage Cohort study (14), in
which a decreasing trend in the incidence
of hypoglycemia hospitalization was
seen. In fact, although our trends were
linear statistically, the incidence of hypo-
glycemia hospitalization did not change
much since 2006 except for the jump in
2010. The Danish study included hypogly-
cemia hospitalization from outpatient, in-
patient, and emergency room visits,
whereas our study only analyzed inpa-
tient data.Wedonot know if hypoglycemia
trends differ by data source in the Danish
study.
In adults with T2DM, notable differ-
ences in trends were found between
young andmiddle-aged adults (i.e., linear
increasing trend) and elderly adults (i.e.,
nonlinear trend), suggesting that age
played a crucial role in diabetes manage-
ment. In addition to the possibly in-
creased vulnerability to hypoglycemia
over time because of aging, the increasing
trend of hypoglycemia hospitalizations in
young and middle-aged adults may be
driven by the convincing microvascular
benefits of tight glycemic control (18)
and diabetes guidelines that individuals
with short diabetes duration, few comor-
bidities, and long life expectancy can be
treatedwithmore stringent glycemic con-
trol (2,39). Further, the primary cause of
death in people with diabetes is cardio-
vascular disease (40,41). Achieving near-
normal glycemic control, even with intensive
therapy,may still be the commonpractice
and the priority. Although speculative,
the decline in the incidence of hypogly-
cemia hospitalization starting in 2009 in
elderly adultswith T2DMmay be driven by
physicians whomay have recently started
to treat a proportion of elderly patients
with T2DM with less stringent glycemic
control who are vulnerable to hypoglyce-
mia. We found that the use of sulfonyl-
ureas decreased all the time among
elderly adults with T2DM, but the decline
stopped around 2007 in young and middle-
aged adults with T2DM. Further, well-
publicized results in 2008–2009 from three
trials (ACCORD [19], ADVANCE [20], and
VADT [21]) suggested that elderly adults
may not gain macrovascular benefits
from aggressive glycemic control; rather,
intensive therapy was associated with in-
creased risk of severe hypoglycemia and
may increasemortality.With a fewexcep-
tions (42,43), most diabetes guidelines
did not emphasize, until very recently,
adjustment of glycemic targets through
evaluating an individual’s hypoglycemia
risk factors (2,3,44).
Lipska et al. (10) had the same hypoth-
esis that the decreasing trend may be
driven by the persuasive findings from
the three trials (19–21). The study of Lipska
et al. was conducted among U.S. Medi-
care beneficiaries$65 years old. The hos-
pital admission rate for hypoglycemia
decreased slightly since 2007 among the
entire sample. The decline occurred earlier
































































































































































































































































































































































































































































with diabetes were analyzed, but diabe-
tes type–specific trend was not reported.
Zaccardi et al. (12) reported an increased
incidence of hospital admissions for
hypoglycemia from 2005 to 2010 and a
relatively stable incidence from 2010
to 2014 in England using the HES data.
Zaccardi et al. (12) did not examine the
trends by diabetes type, although ac-
counting for overall diabetes prevalence
led to a reduction of the hypoglycemia
hospitalization rate from 2010. Our anal-
yses suggest that the decrease in trends
of hypoglycemia hospitalization was only
observed in elderly adultswith T2DM, not
in adultswith T1DMor young andmiddle-
aged adults with T2DM.
Subgroupanalyses in adultswith T2DM
revealed important differences in trends
by current use of glucose-lowering drugs.
In young and middle-aged adults with
T2DM, the incidence of hypoglycemia
hospitalization was considerably higher
among current insulin users than patients
who were currently taking NIGLD only.
Furthermore, the annual increase rate
was also the greatest among current in-
sulin users. Similarly, in elderly adults
with T2DM, subgroups (e.g., current insu-
lin or sulfonylurea users) with markedly
high incidence of hypoglycemia hospital-
ization also had a large annual increase in
trends, contributing to hypoglycemia bur-
den substantially. Although the incidence
of hypoglycemia hospitalization dropped
down in current insulin and NIGLD users
since 2009, the incidence in 2013was still
much higher than that observed in 1998.
In addition, removing them from analyses
did not change the overall nonlinear
trend, suggesting that the declining trend
was not determined by the subgroupwho
was currently taking insulin and NIGLD.
Hypoglycemia requiring hospital ad-
mission only represents ,10% of total
severe hypoglycemia, defined as an event
requiring assistance of another person
(45), and ;25% of emergency depart-
ment visits for hypoglycemia (8). How-
ever, treating hypoglycemic episodes
resulting in hospital admission is expen-
sive and associated with a significant use
of health care resources (17). Approaches
known to effectively reduce the risk of
hypoglycemia include patient education,
dietary and exercise modifications, medi-
cation adjustment, careful glucose moni-
toring by the patient, and conscientious
surveillance by the clinician (1). However,
choosing appropriate strategies for pa-
tients with diabetes should consider
each individual’s diabetes type, hypogly-
cemia risk factors, and long-term health
goals (1–3,46).
Our study provided informative long-
term trend data on the incidence of hypo-
glycemia hospitalization for both adults with
T1DM and adults with T2DM. However,
Figure 2—Incidence and trends in hypoglycemia hospitalization in adults with T1DM (A), young and
middle-aged adults with T2DM (B), and elderly adults with T2DM (C).
limitations should benoted. First,misclas-
sification of diabetes type is a common
problem by using electronic health data.
However, our results were robust and un-
likely to be influenced bymisclassification
error according to the sensitivity analysis
findings. Second, we only studied hypo-
glycemia requiring hospital admission.
Our data may not be applied to severe
hypoglycemia not leading to hospitaliza-
tion. Third, the QOF was launched in
2004, anddiabetes type–specific Read co-
des were used since 2006 rather than the
high-level general Read code for diabetes.
They have resulted in more complete
data recorded in the CPRD and facilitated
the distinction of diabetes type. A study
reported slightly increased T2DM preva-
lence and decreased diagnosis age after
the QOF period (47); adjusting these
changesmight even demonstrate a larger
change in trends, but that is outside the
scope of this work. Fourth, the trends in
HbA1c and other patient characteristics,
such as BMI, may be affected by the miss-
ingdata, particularly in early years (Supple-
mentary Fig. 5A andB). The completeness
of HbA1c and BMI data already noticeably
increased prior to the QOF introduction.
Fifth, the first recorded diabetes visit date
in the CPRD was used as an approxima-
tion for diabetes diagnosis date, which
underestimated the duration of diabetes.
Sixth, it is not clear if hospital admission
criteria for hypoglycemia or the sensitivity
to detect hypoglycemia (e.g., more use of
glucose monitoring devices) might have
changed over time; bothmay impact hos-
pital admission for hypoglycemia. Finally,
drug switching betweendifferent glucose-
lowering drugs over time may be another
factor to explain the observed hypoglyce-
mia trends in England. However, our study
is not powered to study both current drug
users and drug switchers. Current use of
glucose-lowering drugs may be most
relevant to hypoglycemia as an acute
complication.
In conclusion, hypoglycemia that re-
quires hospitalization has been a rapidly
growing burden to the health care system
in England. The incidence of hypogly-
cemia hospitalization increased from
1998 to 2013 in adults with T1DM, and
in young and middle-aged adults with
T2DM. The incidence of hypoglycemia
hospitalization remained high in spite
of the recent decline in elderly adults
with T2DM. Practical approaches for
hypoglycemia management to reverse
the increasing trend of hypoglycemia
hospitalization in England are critically
needed. Studies that are able to investi-
gate diabetes type–specific longitudinal
trendsof severehypoglycemianot resulting
in hospital admission are encouraged. Also,
Figure 3—Trends in HbA1c level in adults with T1DM (A), young andmiddle-aged adults with T2DM
(B), and elderly adults with T2DM (C).
futurework is needed to better understand
the contributors of the hypoglycemia
trends in England, including the decline
from 2009 in elderly patients with T2DM.
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